News

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...
A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system ...
Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...
During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...
The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.
Immunotherapy employs patients' own immune systems to fight cancer, and it has shown itself to be an effective treatment in ...
Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo versus sunitinib.
The KEYNOTE-905 study is ongoing and will evaluate other endpoints including EFS, OS, and pCR rate for neoadjuvant and adjuvant pembrolizumab vs surgery alone.
New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...
The pivotal Phase 3 trial for Cylembio® in advanced melanoma showed clinical improvement in progression free survival, but missed its primary endpoint for statistical significance (p=0.056; threshold ...
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
A research team co-led by UCLA investigators has found that pembrolizumab, an immunotherapy drug that helps the immune system attack cancer cells, can ...